Fighting Antibiotic Resistance with Point of Care Breath Analysis

由于抗生素处方过多，在不能帮助人们好转的情况下，一些细菌已经对它们产生了抗药性。为了减缓这种耐药性，医生需要在抗生素无济于事的情况下少开抗生素。要做到这一点，一种方法是开发一种测试来检测患者是否有细菌感染。这种测试应该是快速、廉价和简单的，既可以在全科医生手术中进行，也可以在医院进行，并且不会给患者带来不便，最好是非侵入性的。需要一种护理点(POC)诊断设备来帮助临床决策使用抗生素。仅仅是能够识别患者是否患有细菌、病毒或真菌感染就可以大大减少用药--关键是让临床医生或全科医生相信不会开出药物--IMSPEX诊断有限公司将进一步开发他们的BreathSpec(R)设备，该设备已经在呼吸道感染患者身上进行了成功的试验。需要进行这些开发，以使BreathSpec(R)设备符合医疗设备的立法。由于这是一个复杂的过程，IMSPEX将得到来自华威大学的领先研究科学家、专业设计工程师和英国国民健康保险制度的帮助。创建一种经济高效、快速且易于使用的测试来确定患者是否患有细菌或病毒胸腔感染。IMSPEX诊断有限公司将向市场推出一种诊断工具，可以帮助管理抗生素并排除不适当的抗生素使用。这将使患者和医生对是否开抗生素的决定都有信心。这一概念非常创新，目前还没有其他公司积极开发使用呼吸分析的AMR测试。这意味着IMSPEX诊断公司有机会率先将此类测试推向市场。

Due to the over prescription of antibiotics in cases where they do not help people get better, some bacteria have become resistant to them. To slow down this resistance, doctors need to prescribe less antibiotics in cases where they will not help. One way to do this is by developing a test to detect if a patient has a bacterial infection or not. This test should be quick, cheap and simple to undertake both at a GP surgery and in hospital and with no inconvenience a patient and preferably non-invasive.There is a need for a point-of-care (POC) diagnostics device to assist clinical decision making in the administration of antibiotics. Simply being able to identify if a patient is suffering from a bacterial, viral or fungal infection could produce a significant reduction in drug administration -- the key is to provide the clinician or GP the confidence NOT to prescribe a drugIMSPEX Diagnostics Ltd will further develop their Breathspec(r) device, which has already been successfully trialled on patients with respiratory tract infections. The developments are needed to make the Breathspec(r) device compliant with legislation for medical devices. As this is a complicated process, IMSPEX will have help from leading research scientists from Warwick University, specialist design engineers and the NHS. Creating a cost-effective, quick and easy-to-use test for deciding if patient have a bacterial or viral chest infection.IMSPEX Diagnostics Ltd will bring to market a diagnostic tool that can assist in antibiotic stewardship and rule out inappropriate antibiotic use. This will give both patients and doctors confidence in the decision to prescribe antibiotics or not. This concept is so innovative that there is currently no other company actively developing an AMR test that uses breath analysis. This means that there is an opportunity for IMSPEX Diagnostics to be first to market with such as test.